S-1/A: iSpecimen Faces Going Concern, Pivots to Solana Treasury

iSpecimen Inc. filed an amended S-1 registration statement, revealing continued net losses, a new Solana-based corporate treasury initiative, and a resale offering of 1.56 million shares by selling stockholders.

Summary

• Amendment No. 3 to Form S-1 (File No. 333-289725) was filed in response to comments from the SEC staff.
• The filing registers for resale 1,559,828 shares of common stock by selling stockholders, including 267,379 shares and 1,292,449 warrant shares.
• The company will not receive proceeds from the sale of common stock by selling stockholders, but may receive up to approximately $129 from the cash exercise of warrants.
• Common stock is listed on the Nasdaq Capital Market under the symbol ISPC, with a last reported sale price of $1.14 per share on October 3, 2025.
• iSpecimen qualifies as an emerging growth company and a smaller reporting company, utilizing reduced public company reporting requirements.
• Plans were announced on August 7, 2025, to establish a corporate treasury reserve of up to $200 million based on the Solana blockchain ecosystem, targeting an initial financing of at least $50 million in Q4 2025.
• A Nasdaq deficiency notice was received on June 4, 2025, for not meeting the minimum stockholders' equity requirement of $2.5 million, with reported equity of $1,668,513 as of March 31, 2025.
• The company reported a net loss of $(1,047,243) for the three months ended June 30, 2025, and $(2,705,639) for the six months ended June 30, 2025.
• Revenue decreased by 75% to $713,135 in Q2 2025 compared to $2,863,679 in Q2 2024, and by 66% to $1,770,645 in H1 2025 compared to $5,153,672 in H1 2024.
• Specimen count decreased by approximately 57% in both Q2 and H1 2025, partly due to a change in revenue recognition policy.
• The company had negative working capital of $4,005,455 and an accumulated deficit of $74,568,256 as of June 30, 2025.
• Cash and cash equivalents totaled $588,775 as of June 30, 2025, a decrease of $1,289,633 from December 31, 2024.
• Management has identified substantial doubt about the company's ability to continue as a going concern.
• Cost-cutting measures include workforce reductions (estimated 146% reduction in monthly compensation costs in 2024 vs. 2023; 76% in H1 2025 vs. H1 2024) and technology cost reductions (64% in 2024 vs. 2023; 71% in H1 2025 vs. H1 2024).
• A legal dispute with former CIO Benjamin Bielak was settled for $215,000 on January 30, 2025.
• The iSpecimen Marketplace platform was shut down from January 25, 2025, through February 12, 2025, due to a legal dispute with Focus Technology Solutions, LLC, which resulted in a court order for pre-judgment security requiring a deposit of 15% of revenue up to $420,000.
• Secured suppliers for human metapneumovirus (hMPV) specimens on January 16, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by recurring and substantial net losses, negative working capital, and a 'going concern' warning. Revenue has sharply declined, and cash reserves are critically low. The Nasdaq non-compliance notice further highlights its instability. While cost-cutting measures are in place, the new Solana-based treasury program introduces significant, unhedged exposure to a highly volatile and unregulated asset class, which is a major distraction from its struggling core business. Ongoing legal disputes and operational disruptions (like the platform shutdown) underscore severe execution risks.

Positives

• Successfully implemented a next-day quote system in Q3 2023, leading to a 43% increase in conversion ratios of quotes to purchase orders.
• Significant cost-cutting measures have been implemented, resulting in estimated reductions in monthly compensation costs of 146% in 2024 compared to 2023, and 76% in H1 2025 compared to H1 2024.
• Technology costs were also significantly reduced by an estimated 64% in 2024 compared to 2023, and 71% in H1 2025 compared to H1 2024.
• Completed a supplier network refresh project, focusing on high-value suppliers and re-engaging them more effectively.
• Strategic business intelligence initiatives are enabling a better understanding of the market and data-driven growth strategies.
• Regained compliance with Nasdaq's minimum bid price requirement on October 1, 2024.
• Secured suppliers for human metapneumovirus (hMPV) specimens, addressing a potential high-demand research area.

Negatives

• Incurred significant recurring net losses, with $(12,497,805) in 2024 and $(11,099,488) in 2023, and $(2,705,639) in H1 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows from operations, and a significant accumulated deficit.
• Revenue decreased significantly by 75% in Q2 2025 and 66% in H1 2025 compared to the same periods in the prior year.
• Specimen count decreased by approximately 57% in both Q2 and H1 2025, partly due to a change in revenue recognition policy.
• Average selling price decreased by 42% in Q2 2025 and 21% in H1 2025.
• Working capital deficit worsened to $(4,005,455) as of June 30, 2025.
• Cash and cash equivalents decreased to $588,775 as of June 30, 2025, from $1,878,408 at December 31, 2024.
• Received a Nasdaq deficiency notice on June 4, 2025, for failing to meet the minimum stockholders' equity requirement of $2.5 million.
• Identified a material weakness in internal control over financial reporting related to sales tax collection and remittance.
• Incurred losses from sales tax obligations in prior years due to failure to collect taxes, with uncertainty about recovering from all customers.
• Reliance on a limited number of customers for a significant portion of revenue (one customer accounted for 29% in 2024 and 25% in 2023).
• Revenue is transactional and not recurring, making future forecasting difficult.
• Customer retention rates are moderate, with 64% of top 25 customers from 2023 procuring in 2024.
• Investment in technology development has been significantly reduced in 2025 ($0 capitalized in H1 2025 vs. $448,000 in H1 2024).
• Ongoing legal disputes, including a platform shutdown by Focus Technology Solutions, LLC, and a court order for pre-judgment security.
• The war between Russia and Ukraine negatively impacted business in H1 2022, causing $1 million in purchase order delays and affecting margins.
• Senior management team has limited experience managing a public company, potentially diverting attention to regulatory compliance.
• The new Solana-based corporate treasury program introduces significant, unhedged exposure to a highly volatile and uncertain digital asset market, with risks including price volatility, regulatory uncertainty, and custody/cybersecurity concerns.

Risks

• Incurred losses since inception and anticipate continued losses for the foreseeable future, may never achieve or sustain profitability.
• Substantial doubt about the ability to continue as a going concern.
• Identified a material weakness in internal control over financial reporting related to sales tax documentation, calculation, collection, reporting, and remittance.
• May require additional capital in the future, and an inability to meet future capital needs could adversely impact operations.
• Revenue trend is not predictive, and the ability to accurately forecast future results is limited by transactional revenue, customer concentration, project-based needs, and supplier fulfillment delays.
• Growth strategy may not prove viable, including expansion of platform capabilities, customer/supplier base, and new lines of business (patient recruitment, data licensing).
• International operation expansion exposes the company to additional risks such as changes in local political/economic conditions, trade restrictions, currency fluctuations, and difficulties in contract enforcement.
• Adverse effects from external events like severe weather, natural disasters, health epidemics, acts of war or terrorism (e.g., Russia-Ukraine war) for which business continuity plans may not adequately prepare.
• Technology platform defects or failures could lead to service suspension, diversion of development resources, and harm to business and reputation.
• Sustainable future revenue growth is dependent upon the development of technology solutions that enable scale and address new markets; the platform may become technologically obsolete or commoditized.
• Security measures breaches or attacks could lead to loss of information, litigation, potential liability, and damage to reputation.
• Changes in demand for products and services due to economic downturns, changes in disease landscape, drug/therapy developments, diagnostic tests, data requirements, or competitive offerings could affect profitability.
• Credit risk with customers, particularly privately held, investor-backed biopharma companies, may result in non-payment.
• Reliance on relatively few customers for a significant portion of revenue; loss of large customers could affect the ability to operate.
• Customers and customer prospects may be averse to using a self-service marketplace, requiring iSpecimen personnel involvement, which impacts scalability and profitability.
• Reduction, delay, or cancellation of orders from customers due to project changes, budget issues, or procurement from multiple sources.
• Contracts with U.S. government agencies and contractors subject to federal contract and audit risks, including unilateral termination and audit of costs.
• Sustainable future revenue growth is dependent on growth in the capabilities of the supply network, which is currently supply-constrained.
• Failure to gain access to more healthcare data from the supply network may adversely affect growth.
• The adoption cycle of the supply network tends to be lengthy, which may adversely affect the ability to scale rapidly and increase revenues.
• Potential adverse effects from changes in the healthcare industry, including consolidations and regulatory changes, could affect access to subjects, samples, and data.
• The supply chain may not provide adequate resources to quickly respond to requests for specimens, leading to delays, reputational damage, and impact on revenue and profitability.
• Does not control the end-to-end quality of specimens and data collected in the supply chain; quality issues can affect reputation, revenue, and profitability.
• Reliance on relatively few supply partners for significant supplies and services could affect the ability to operate and grow.
• Specimen collection from human subjects, including the possible occurrence of adverse events, could provide exposure to claims and litigation.
• Reliance on international organizations to collect and distribute specimens and data in accordance with local regulations, introducing compliance risk.
• Delays or interruption in the shipments of specimens due to factors outside of control (e.g., weather, natural disasters, military conflicts, customs delays).
• The war between Russia and Ukraine negatively impacted business and continues to pose uncertainty for suppliers in those regions.
• Future success depends on the ability to retain key personnel and to attract, retain, and motivate qualified personnel.
• Senior management team has limited experience managing a public company, and regulatory compliance may divert attention from day-to-day management.
• Competitors may have greater resources, outspend, or develop superior technology solutions, intensifying competition.
• May lose business to competitors which have or develop their own biorepositories and/or collection centers that can meet customers' needs more quickly.
• May face pricing pressure from competitors who may lower prices to reduce biorepository inventories or due to more favorable specimen acquisition costs.
• Overall business results may suffer from an economic downturn, reducing research and development spending by biopharma companies.
• Results of operations and financial condition may be adversely impacted from high inflation rates, particularly on employee salaries and operating costs.
• Difficulty managing growth in business could adversely affect financial condition and results of operations.
• Incurred losses from sales tax obligations owed to various jurisdictions in prior years, and may never be able to recover these taxes from all customers.
• Acquisitions of other businesses, products, or technologies could disrupt business, reduce financial resources, or cause dilution to stockholders.
• May incur significant debt, and governing documents contain no limit on the amount of debt that may be incurred.
• Failure to comply with restrictive covenants in the Purchase Agreement or other financing arrangements would have a material adverse effect.
• Failure to regain compliance with Nasdaq's continued listing standards could result in delisting, reducing liquidity and impairing capital raising ability.
• Use of third-party technology licenses as part of the technology solution; no assurance of continued availability on acceptable commercial terms.
• Use of open-source licenses may subject the company to claims from third parties claiming ownership and unauthorized use.
• May become subject to third parties' claims alleging infringement of their patents and proprietary rights.
• Does not have any patents protecting intellectual property; relies on trade secrets, which are difficult to protect.
• Failure to comply with federal and state data protection regulations (e.g., HIPAA) could result in fines, penalties, and litigation.
• Failure to comply with international laws related to data protection (e.g., GDPR) could result in fines, penalties, and litigation.
• Failure to comply with federal and state laws around environmental, health and safety, biohazards, dangerous goods, and imports/exports could result in fines, penalties, and litigation.
• Failure to comply with other international laws around environmental, health and safety, biohazards, dangerous goods, and imports/exports could result in fines, penalties, and litigation.
• Failure to comply with laws and regulations related to the protection of research subjects (e.g., Common Rule, FDA regulations) could result in fines, penalties, and litigation.
• Failure to comply with other laws and regulations related to business operations (e.g., Occupational Safety and Health, CDC Import Permit, IATA Dangerous Goods, Anti-Kickback Statute, tax/tariff rules) could have a material adverse effect.
• Product safety and product liability, including bio-hazard risks, could provide exposure to claims and litigation.
• No assurance that an active and liquid trading market for common stock will continue or that Nasdaq's continued listing standards will be met.
• If common stock is delisted, it could be more difficult for stockholders to sell shares, liquidity would be reduced, and ability to raise additional capital could be impaired.
• If common stock is delisted, it may be considered a 'penny stock,' subjecting it to rules that reduce liquidity.
• Certain provisions of the certificate of incorporation and bylaws may make it more difficult for a third party to affect a change-of-control.
• Bylaws designate certain courts as the sole and exclusive forum for certain types of actions, which could limit stockholders' ability to obtain a favorable judicial forum.
• Limitations on director and officer liability and indemnification may discourage stockholders from bringing suit against an officer or director.
• Do not expect to pay dividends in the foreseeable future; any return on investment may be limited to the value of common stock.
• May need additional capital, and the sale of additional shares of common stock or other equity securities could result in additional dilution to stockholders.
• Quarterly revenue tends to fluctuate, making it harder to forecast and meet investor expectations.
• Stock price may be volatile.
• Status as an emerging growth company may make it more difficult to raise capital or make common stock less attractive to investors.
• Limited insurance may not cover claims by third parties against the company or its officers and directors.
• The requirements of being a U.S. public company may strain resources and divert management's attention.
• Evaluation of internal control and remediation of potential problems will be costly and time-consuming and could expose weaknesses in financial reporting.
• Public company compliance may make it more difficult to attract and retain officers and directors.
• The sale of a substantial amount of common stock, including resale by selling stockholders, could adversely affect the market price of common stock.
• The plan to establish a Solana-based corporate treasury program exposes the company to significant risks associated with digital assets, including volatility and competition from other digital assets.
• May not be successful in raising sufficient capital to fund the Treasury Program.
• The regulatory environment for digital assets is uncertain and evolving.
• Custody and cybersecurity risks could lead to a partial or total loss of digital assets.
• Purchase strategy may expose the company to additional risks, including illiquidity associated with Locked SOL.
• Involvement in digital assets may subject the company to reputational risk.
• No assurance as to the timing, size, form, or success of the Treasury Program.
• Absent federal regulations, there is a possibility that SOL may be classified as a security, subjecting the company to additional regulation.
• If deemed an investment company under the 1940 Act, applicable restrictions likely would make it impractical to continue segments of the business as currently contemplated.
• No hedging of Solana exposure, leaving the company fully exposed to volatility.
• Staking Solana could limit liquidity and expose the company to additional risks.
• No history in generating staking revenues from Solana.
• Plans to pursue staking and liquid staking strategies expose the company to additional competition, counterparty, and operational risks.
• If pursuing income-generating strategies with Solana other than staking, such activities could expose the company to significant additional risks.
• The pursuit of a Solana-based treasury program and other crypto asset activities could distract from core biospecimen marketplace operations and expose the company to significant risks.
• Plans to diversify into other digital assets beyond Solana may expose the company to additional risks.
• Potential spot trading activities could increase volatility and the risk of losses.

Future Outlook

The company plans to continue investing in its iSpecimen Marketplace platform to enhance performance, functionality, and ease of use, aiming to improve matchmaking, support prospective collections, deepen search and workflow capabilities, increase automation, and enable direct pricing. It is also exploring adjacent business models like 'data as a product.' A significant strategic initiative involves establishing a Solana-based corporate treasury program, with plans to raise up to $200 million over the next 1-2 years, including an initial financing of at least $50 million in Q4 2025. Management intends to continue cost-cutting measures, streamline operations, and re-organize the commercial business with a new account-based sales approach and an outbound sales team to drive revenue growth and improve financial predictability. The company's ability to continue as a going concern is dependent on generating additional revenues and securing further financing.

Management Comments

• Our mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and associated data.
• Our vision is to create an Amazon-like global Marketplace of patients, biospecimens, and data for research to improve the quality of human life.
• We believe with additional investment in technology development resources, we could make significant progress in scaling our iSpecimen Marketplace.
• We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects.
• Managements plan to mitigate the conditions that raise substantial doubt includes generating additional revenues, deferring certain projects and capital expenditures and eliminating certain future operating expenses for the Company to continue as a going concern.
• We believe that SOL is not a security but neither the SEC nor any other U.S. federal or state regulator publicly stated whether they agree with our assessment.
• Our primary objective in acquiring Solana is to diversify our balance sheet and support long-term growth initiatives, rather than to engage in speculative trading.
• Our core business remains the operation of our global marketplace platform connecting patients, biospecimens, and data with researchers.

Industry Context

The biospecimen procurement market is highly fragmented and inefficient, which iSpecimen aims to transform with its online marketplace, drawing parallels to the disruptive impact of travel websites on consumer buying. The increasing pursuit of precision medicine in healthcare and life science industries is driving high demand for human biospecimens and associated clinical data. Competition is fragmented, with many small providers, but larger, well-capitalized biospecimen providers are consolidating the industry, posing a significant competitive threat. The company operates in highly regulated environments, including healthcare and clinical research, necessitating compliance with complex data protection (HIPAA, GDPR), human subject research (Common Rule, FDA), and other international and domestic laws. The new venture into digital assets, specifically Solana, places the company in a highly volatile, uncertain, and evolving regulatory landscape, distinct from its core biospecimen business.

Comparison to Industry Standards

• The iSpecimen Marketplace aims to be an 'Amazon-like global Marketplace,' suggesting a comparison to leading e-commerce platforms for ease of use and comprehensive offerings, which is a high standard for B2B procurement.
• The company compares its transformation of biospecimen procurement to how 'travel websites changed the consumer buying process for flights, hotels, and rental cars,' implying a similar disruptive and efficiency-driving impact on a traditionally manual industry.
• Its search capabilities are highlighted as a distinguishing factor from other B2B bioprocurement marketplaces, which typically only list service providers rather than specific available specimens, suggesting a more advanced technological offering.
• The company believes its 'technology-based approach will allow us to scale faster than our competitors who rely upon manual efforts to procure specimens,' positioning its platform as a competitive advantage in scalability.
• Biomarker companion diagnostic discovery and development, which utilizes biospecimens, is cited as reducing drug clinical trial costs by 30% to 60% according to Ark Research, indicating the significant value proposition of iSpecimen's products in the broader life science industry.
• Acknowledges that many competitors maintain their own biorepositories or collection centers, which provides a 'time-to-delivery advantage' over iSpecimen's 'just in time' procurement model, indicating a potential competitive disadvantage in speed for certain requests.

Management Changes

Corporate Governance

Legal Proceedings

• Benjamin Bielak (Former CIO) initiated a Demand for Arbitration on July 25, 2024, claiming $586,800 for alleged bonus and severance payments. The matter was settled for $215,000 on January 30, 2025.
• Focus Technology Solutions, LLC filed a complaint on December 9, 2024, alleging non-payment of approximately $489,572 for IT services. Focus disabled the iSpecimen Marketplace from January 25, 2025, to February 12, 2025. A settlement agreement was reached on February 11, 2025, for $500,000, but Focus failed to fully restore the platform. The company notified Focus of breach on February 28, 2025, and withheld payments. On April 10, 2025, the Court partially granted Focus's motion for pre-judgment security, requiring the company to deposit 15% of revenue up to $420,000. The company intends to assert counterclaims for consequential damages.
• Azenta US, Inc. initiated a claim on or around January 15, 2025, for $651,262, alleging breach of contract and unjust enrichment. The company believes these claims are without legal or factual basis and intends to vigorously defend them.
• EGSEllenoff Grossman & Schole LLP initiated a claim on or around November 14, 2024, for $425,684, alleging breach of contract and compensation. The company believes these claims are without legal or factual basis and intends to vigorously defend them, currently engaged in settlement discussions.

Related Party Transactions

• No material related party transactions exceeding the lesser of $120,000 or 1% of average total assets were disclosed for the fiscal years ended December 31, 2024 and 2023, nor are any currently proposed.

Stakeholder Impact

• Shareholders face potential dilution from past and future equity offerings, including the recent public and private placements and the planned Solana treasury financing. There is a significant risk of delisting from Nasdaq due to non-compliance with listing standards, which would reduce stock liquidity. The company does not anticipate paying dividends in the foreseeable future, limiting investment returns to stock price appreciation. The high-risk Solana treasury program introduces additional speculative exposure.
• Employees have been impacted by workforce reductions as part of cost-cutting measures, although stock-based compensation plans are in place to incentivize personnel.
• Customers may experience reduced demand for biospecimens due to broader economic downturns, changes in research needs, or competitive offerings. The iSpecimen Marketplace experienced a shutdown due to a legal dispute, disrupting service. However, customers may benefit from the implemented next-day quote system and efforts to improve operational efficiency.
• Suppliers, particularly those in Ukraine and Russia, have been impacted by geopolitical conflicts, leading to supply chain disruptions and changes in unit economics. The company is focusing on a 'supplier network refresh' to engage high-value partners more effectively.
• Creditors face increased risk due to the company's substantial doubt about its ability to continue as a going concern, recurring losses, and negative working capital. The company is subject to restrictive covenants in its financing arrangements.

Next Steps

• Continue to invest in the development of the iSpecimen Marketplace platform to enhance performance, functionality, ease of use, and reliability.
• Improve matchmaking across the platform, support prospective collections, deepen search and workflow capabilities, increase automation, and enable direct pricing availability.
• Explore adjacencies that leverage the platform, including a 'data as a product' model.
• Implement the Solana-based corporate treasury program, including raising approximately $200 million over 1-2 years, with an initial financing of at least $50 million targeted in Q4 2025.
• Continue efforts to decrease capital and operational expenditures, including managing workforce and technology costs.
• Re-organize the commercial end of the business with a new account-based sales approach and the introduction of an outbound sales team.
• Bring marketing and sales closer to enable efficiencies within the commercial organization.
• Leverage strategic business intelligence to understand market needs and adjust supplier network and marketing efforts.
• Continue to seek relief from the court-ordered pre-judgment security in the Focus Technology Solutions, LLC dispute and assert counterclaims.
• Continue settlement discussions with EGSEllenoff Grossman & Schole LLP.
• Vigorously defend claims by Azenta US, Inc.
• Address Nasdaq's deficiency notice regarding minimum stockholders' equity by implementing the compliance plan.

Key Dates

Recommendation

iSpecimen Inc. is in a critical financial state, marked by recurring and substantial net losses, a significant decline in revenue, negative working capital, and critically low cash reserves. The 'going concern' warning from its auditors and the Nasdaq non-compliance notice underscore severe financial instability and a high risk of delisting. While management is implementing cost-cutting measures, the new, highly speculative Solana-based corporate treasury program introduces unhedged exposure to an extremely volatile and unregulated asset class, which is a significant distraction from its struggling core business. Ongoing legal disputes, including a platform shutdown and court-ordered pre-judgment security, indicate operational fragility and further financial strain. The combination of severe financial distress, high operational risk, and a speculative, unrelated new venture makes the stock a very high-risk investment with a strong likelihood of further capital erosion.

Keywords

Biospecimen, Life Science Research, Marketplace Platform, Solana, Digital Assets, Biotechnology, Healthcare, SEC Filing, S-1/A, Nasdaq, ISPC, Financial Reporting, Corporate Governance, Risk Management, Private Placement, Warrants, Emerging Growth Company, Smaller Reporting Company, Revenue, Net Loss, Working Capital, Going Concern, Internal Controls, Sales Tax, Legal Proceedings, Supply Chain, Cybersecurity, Data Protection, HIPAA, GDPR, Executive Compensation, Stock Options, Restricted Stock Units, Capital Raise, Dilution